IPWatchdog.com is in the process of transitioning to a newer version of our website. Please be patient with us while we work out all the kinks.

Cellspin Soft Challenges Denials of USPTO Director Review Under Arthrex and APA

“[Cellspin Soft’s appeal] underscores the need for the Biden Administration to ensure that his nominee for USPTO Director is confirmed as soon as possible.”

https://en.wikipedia.org/wiki/United_States_Patent_and_Trademark_OfficeLast week, patent owner Cellspin Soft filed a citation of supplemental authorities with the U.S. Court of Appeals for the Federal Circuit (CAFC) asking the appellate court to either vacate or reverse an order from the U.S. Patent and Trademark Office (USPTO) denying Director review following a pair of inter partes review (IPR) proceedings conducted at the Patent Trial and Appeal Board (PTAB). Cellspin Soft is challenging the USPTO’s denial as invalid both under the Administrative Procedures Act (APA), as well as under the U.S. Supreme Court’s precedent in United States v. Arthrex (2021).

Cellspin had filed requests seeking Director review of a pair of final written decisions invalidating all challenged claims of U.S. Patent No. 9258698, Automatic Media Upload for Publishing Data and Multimedia Content. It claims a machine-implemented method of media transfer utilizing a digital data capture device and a Bluetooth-enabled mobile device for publishing multimedia content automatically onto a website with minimal user intervention. Issued to Cellspin Soft in February 2016, the ‘698 patent has been asserted in infringement suits filed in U.S. district courts against several defendants including Panasonic, GoPro, Garmin, Nikon, Canon and Eastman Kodak.

On October 30, 2018, two IPR petitions were filed at the PTAB challenging claims of the ‘698 patent by Panasonic Corporation and Canon USA. Two other IPR petitions were filed by GoPro and Garmin and those IPRs were instituted and then terminated after the PTAB approved motions to join GoPro and Garmin to both of the two previous IPRs on the ‘698 patent. In a pair of final written decisions issued in late April 2020, the PTAB found that all challenged claims in both the Panasonic and Canon IPRs were unpatentable as obvious in light of the asserted prior art. The PTAB also denied motions to strike filed by both petitioners and patent owners in those IPRs, including Cellspin Soft’s motion to strike what it alleged were new arguments of unpatentability raised in the petitioner’s reply brief.

Cellspin Soft filed notices of appeal in June 2020 to seek Federal Circuit review of the PTAB’s final written decisions in both the Panasonic and Canon IPRs. In the notices of appeal, Cellspin Soft indicated that it was raising several legal issues with the PTAB’s obviousness determination, including the Board’s use of a novel obviousness theory as well as violations of the Administrative Procedures Act and the Appointments Clause of the U.S. Constitution. Those latter two points are expanded upon in Cellspin Soft’s recent citation of supplemental authorities filed pursuant to Federal Rule of Appellate Procedure 28(j), which authorizes a party who has already filed an appellate brief to present pertinent and significant authorities that later comes to the party’s attention. The filing follows about a week after an order denying Cellspin Soft’s requests for Director review of the final decisions.

Cellspin: Denial Should Be Invalidated for Lack of Sufficient Explanation, Lack of Director Authority

The Appointments Clause arguments brought by Cellspin Soft in the citation of supplemental authorities follow the Supreme Court’s ruling in Arthrex, which was issued this past summer. First, Cellspin Soft argues that there is no indication of the individual who decided that Director review of the final written decisions in question would be denied. Cellspin Soft cites several passages from Arthrex, which held that the unreviewable authority of administrative patent judges (APJs) at the PTAB violated the Appointments Clause and required review of APJ final decisions by the USPTO Director, indicating that the Director would be responsible for review of all final decisions by the PTAB. Cellspin Soft argues that this differs from patents issued by the agency, which are signed by the Director or, as has been the case during the current absence of a USPTO Director, someone with authority at the agency for granting patents.

Further, Cellspin Soft argues that if if the denial was decided by Drew Hirshfeld, currently performing the functions and duties of the USPTO Director, then the denial is invalid under Arthrex because Hirshfeld is not a principal officer of the United States who has been appointed to his position without the advice and consent of the U.S. Senate. This failure to appoint APJs by the Senate’s advice and consent, coupled with the unreviewable authority of APJs, created the constitutional issue under the Appointments Clause that the Supreme Court sought to remedy in its Arthrex decision. Although President Biden has appointed Kathi Vidal to serve as the Director of the USPTO pending her confirmation by the Senate, Hirshfeld was officially the Commissioner of Patents at the USPTO at the time the denial was issued late this November and his authority is arguably not consistent with the constitutional mandate under the Appointments Clause. While the order denying Director review is unsigned, the document does indicate that the matter was before Hirshfeld for his consideration.

Cellspin Soft raises additional arguments under the APA, including the agency’s failure to provide a sufficient explanation for its denial as required by 5 U.S.C. § 555(e). Under this statute, an agency is required to issue a brief statement of grounds for a denial when denying a request by an interested person in an agency proceeding, except where the denial is self-explanatory or is issued in affirmation of a previous denial. The three-page order issued by the USPTO denying Director review simply indicates that review of the IPR final written decisions was the subject of Cellspin Soft’s request, that the request was denied and that the final written decisions in those IPRs are the final decision of the agency.

Can the USPTO Implement an Effective Process for Full Review of PTAB Decisions?

Finally, Cellspin Soft argues that the entire process for Director review of PTAB decisions is procedurally deficient because it was implemented without notice-and-comment rulemaking as required under 5 U.S.C. § 552(a)(1). A similar argument was raised by Google and Apple in a lawsuit filed in U.S. district court challenging the USPTO’s developing of the Fintiv framework for discretionary denials of PTAB trials based on corresponding district court patent litigation. In November, U.S. District Judge Edward J. Davila of the Northern District of California granted the USPTO’s motion to dismiss the case, ruling that recent Supreme Court precedent on the unreviewability of PTAB decisions from cases including Cuozzo Speed Technologies v. Lee (2016) and Thryv v. Click-to-Call Technologies (2020) also extends to discretionary denials of PTAB petitions.

It seems reasonable to suggest that denying review of final PTAB decisions without an explanation doesn’t seem to adhere to the spirit of Arthrex, which sought to increase accountability over APJ decision-making. At the same time, the incredible size of the PTAB’s docket and the large number of PTAB decisions that are appealed would seem to make it impossible for the Director to consider the issues and render a full written explanation on each request for review. The situation underscores the need for the Biden Administration to ensure that his nominee for USPTO Director is confirmed as soon as possible.

 

 

Share

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Join the Discussion

15 comments so far. Add my comment.

  • [Avatar for Anon]
    Anon
    December 8, 2021 08:54 am

    As to, “First, Cellspin Soft argues that there is no indication of the individual who decided that Director review of the final written decisions in question would be denied. …

    I do believe that I was the very first one in the patent blogosphere to raise the point that Mr. Hirshfeld lacks the specific Constitutional Appointments Clause authority for the type of review mandated by the Court (even if such mandating by the Court is an ultra vires act of rewriting legislation from the bench).

    It is likely a bit of a shallow victory with Vidal so likely to take the reigns in short order, but the Means (especially in law) must be proper to get to whatever Ends are arrived at at the end of the day.

  • [Avatar for J. Doerre]
    J. Doerre
    December 8, 2021 11:53 am

    Anon,

    See United States v. Eaton, 169 U.S. 331, 343 (1898) (“Because the subordinate officer is charged with the performance of the duty of the superior for a limited time and under special and temporary conditions, he is not thereby transformed into the superior and permanent official. To so hold would render void any and every delegation of power to an inferior to perform under any circumstances or exigency the duties of a superior officer, and the discharge of administrative duties would be seriously hindered.”);

    See also Edmond v. United States, 520 U.S. 651, 661 (1997) (“Among the offices that we have found to be inferior are that of … a vice consul charged temporarily with the duties of the consul.” (citing Eaton, 169 U.S. at 343))

  • [Avatar for Anon]
    Anon
    December 8, 2021 08:08 pm

    Thank you Mr. Doerre, and as you are no doubt aware (through the writings of the illustrious Mr. Boundy), the Executive Branch dominion of the Patent Office is bound by a number of Administrative Procedure laws as to the duration and ‘depth’ of duties of ‘temporary’ transfers of authority.

    It is without a doubt that such provide strict limits on Mr. Hirschfeld, an entirely un-appointed and unvetted civil servant.

    (there is a reason for the ‘game-playing’ in his “official” title during this transition)

    Here’s a hint: this legally does not end well for the Patent Office.

  • [Avatar for Herb Wamsley]
    Herb Wamsley
    December 9, 2021 07:59 am

    The USPTO’s order of November 22 said, “It is ORDERED that the request for Director review is denied . . . .” Arthrex appears to require the Director to review every request personally. The order said the request was “before” Mr. Hirshfeld, so he may have reviewed it, but the wording of the order is not the best.

  • [Avatar for B]
    B
    December 9, 2021 09:53 am

    @ Anon “It is without a doubt that such provide strict limits on Mr. Hirschfeld, an entirely un-appointed and unvetted civil servant.”

    It makes one wonder what the muckity-mucks at the PTO were thinking. Don’t they have any in-house attorneys?

  • [Avatar for Patent Investor]
    Patent Investor
    December 10, 2021 09:01 am

    @B it makes you wonder what in the world CJ Roberts was thinking when he spent pages and pages pontificating about the political accountability of presidentially appointed and senate confirmed superior officers and then remanded to the “acting director” when the whole world knew that Hirshfeld didn’t even have than title

  • [Avatar for Anon]
    Anon
    December 10, 2021 12:28 pm

    Patent Investor,

    I invite you to reread the actual words of the Supreme Court decision, as there was no such directed remand to a person lacking the noted confirmation process — this is precisely why any action by Hirschfeld is improper (and provides the legal basis for changing decisions by the Patent Office, made with or without explicit ties to Hirschfeld).

    As I have often stated, the Ends do not justify the Means — especially in law; and this is a clear case in which the Means MUST be proper.

  • [Avatar for Anon]
    Anon
    December 10, 2021 12:30 pm

    B,

    And it is not as if those solicitors (had they been following this and other patent law blogs) were unaware, as I mentioned, this was noted quite clearly after the Supreme Court decision.

  • [Avatar for Patent Investor]
    Patent Investor
    December 10, 2021 06:09 pm

    @Anon, help me out here. How else to interpret:

    >>>We also conclude that the appropriate remedy is a remand to the Acting Director for him to decide whether to
    rehear the petition filed by Smith & Nephew…Under these circumstances, a limited remand to the Director provides an adequate opportunity for review by a principal officer<<>>The judgment of the United States Court of Appeals for
    the Federal Circuit is vacated, and the cases are remanded
    for further proceedings consistent with this opinion. <<<

  • [Avatar for Anon]
    Anon
    December 12, 2021 09:05 pm

    You do know that Hirschfeld has never been the Acting Director, right?

    Check how the Office ‘played their games’ with how Hirschfeld was ‘titled’ (and these games have everything to do with Administrative Agency rules on temporary powers).

  • [Avatar for Patent Investor]
    Patent Investor
    December 13, 2021 06:45 pm

    I totally understand that. But roberts remanded it to the acting director, not hirshfeld.

  • [Avatar for Anon]
    Anon
    December 14, 2021 05:25 pm

    And PI, you then understand that Roberts’ words have no real meaning, given that no such position is occupied (nor will be).

    The gist of the decision CENTERS on having a proper chain of authority – for Constitutional reasons. Roberts has no power to rewrite that document.

Add Comment

Your email address will not be published.